Cellular Senescence and Iron Dyshomeostasis in Alzheimer's Disease

• Main Authors: Shashank Masaldan (Author), Abdel Ali Belaidi (Author), Scott Ayton (Author), Ashley I. Bush (Author)
• Format: Book
• Published: MDPI AG, 2019-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1424-8247; 10.3390/ph12020093
• Keywords: Alzheimer's disease; iron homeostasis; ferroptosis; senescence; chelators; Medicine; R; Pharmacy and materia medica; RS1-441
• Source: Pharmaceuticals, Vol 12, Iss 2, p 93 (2019)

Iron dyshomeostasis is a feature of Alzheimer’s disease (AD). The impact of iron on AD is attributed to its interactions with the central proteins of AD pathology (amyloid precursor protein and tau) and/or through the iron-mediated generation of prooxidant molecules (e.g., hydroxyl radicals). However, the source of iron accumulation in pathologically relevant regions of the brain and its contribution to AD remains unclear. One likely contributor to iron accumulation is the age-associated increase in tissue-resident senescent cells that drive inflammation and contribute to various pathologies associated with advanced age. Iron accumulation predisposes ageing tissue to oxidative stress that can lead to cellular dysfunction and to iron-dependent cell death modalities (e.g., ferroptosis). Further, elevated brain iron is associated with the progression of AD and cognitive decline. Elevated brain iron presents a feature of AD that may be modified pharmacologically to mitigate the effects of age/senescence-associated iron dyshomeostasis and improve disease outcome.